In cell-based laboratory experiments, AOD9604 has been shown to influence AMPK-associated metabolic pathways , leading to measurable shifts in substrate utilization and energy-related biochemical markers
Key metabolic effects include: Enhanced lipolysis through activation of fat breakdown pathways independent of growth hormone receptors Suppressed lipogenesis reducing conversion of non-fat substrates into stored fat Increased fat oxidation and energy expenditure in multiple species models No adverse effects on insulin sensitivity or glucose metabolism, unlike full-length growth hormone Independence from IGF-1 Signaling A critical distinction of AOD-9604 is its lack of IGF-1 pathway activation: No measurable changes in serum IGF-1 levels in human clinical trials Absence of growth-promoting effects on tissues No impact on blood glucose regulation or insulin resistance Avoidance of typical growth hormone side effects including edema and tissue overgrowth Metabolic Pathway Modulation Research indicates AOD-9604 influences energy metabolism through multiple mechanisms: Increased whole-body fat oxidation rates in animal models Enhanced metabolic rate without stimulant-like effects Potential modulation of uncoupling proteins in adipose tissue Effects on lipid metabolism that persist beyond plasma clearance Critical Mechanistic Gap: Despite extensive research, the primary receptor target for AOD-9604 remains unidentified
Long-Term Outcomes and Considerations Sustainable Weight Loss Peptides can support sustainable weight loss when combined with balanced nutrition, regular exercise, and healthy lifestyle habits
CJC-1295 (when with DAC) appears to possess a longer half-life of about 6-8 days, which would mean a sustained increase in growth hormone levels
Data Availability Statement No datasets were generated or analyzed during the current study.
